Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended-release niacin/laropiprant added to ongoing lipid-modifying therapy in primary hypercholesterolemia or mixed dyslipidemia
2010-021627-27Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of niacin and laropiprant in hypercholesterolemia and combined dyslipidaemia (2 arms), sponsored by Merck & Co. Primary endpoint: Low-density lipoprotein cholesterol at Week 12. Started Jan 2011; status: terminated.
02
Drugs
niacinlaropiprant
03
Conditions
hypercholesterolemiacombined dyslipidaemia
Beyond the preview
Go deeper on 2010-021627-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021627-27.